BYU to build School of Medicine at site of former Provo High School
PROVO, Utah () — Brigham Young University's new School of Medicine has been approved to take the place of the old Provo High School on the university's West Campus.
The former high school and its 25 acres of property were . Since then, the campus has been used by the College of Fine Arts and Communications (CFAC), but it will now be home to a new building for the School of Medicine.
BYU said the planning and construction of the BYU School of Medicine will not interfere with CFAC students or operations. CFAC students, faculty and staff will stay in the former high school until the new BYU Arts Building can be completed.
Dr. Mark J. Ott, who was named as the inaugural dean of the medical school in October 2024, said there were 'many deeply committed people' moving this work forward.
This Utah city is one of 2025's hottest summer travel destinations: WalletHub
The First Presidency of the Church of Jesus Christ of Latter-day Saints announced at the Provo-based college in July 2024. The new medical school will include training and research to 'address international health issues and support the Church of Jesus Christ's worldwide humanitarian efforts,' according to BYU.
While there are no plans for BYU to create its own hospital or hospital system, the new School of Medicine will reportedly work closely with Intermountain Health at its Utah Valley hospital, as well as the University of Utah.
'Since its announcement, the BYU School of Medicine has received tremendous interest,' said BYU President C. Shane Reese. 'We appreciate the enthusiasm and support for the BYU School of Medicine from people and organizations across the world.'
Once completed, BYU's School of Medicine will offer a Doctor of Medicine degree. School officials said in September 2024 that Dr. Ott and the school were exploring 'innovative approaches' to reduce graduation times and costs for students.
Four lanes blocked by crash on I-15 in Salt Lake City
KTVX-KUCW'S Disneyland 70th Celebration Sweepstakes
KTVX-KUCW's Harry Potter: The Exhibition Sweepstakes
BYU to build School of Medicine at site of former Provo High School
Real Monarchs fall to Rapids 2 in stoppage time heartbreaker
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Boston Globe
3 hours ago
- Boston Globe
Will Trump's policies kill Massachusetts' life sciences leadership?
Advertisement Although the industry is centered in eastern Massachusetts, there's a statewide benefit from all the tax dollars those businesses and workers pay. Get The Gavel A weekly SCOTUS explainer newsletter by columnist Kimberly Atkins Stohr. Enter Email Sign Up In all, Massachusetts organizations — including universities, research institutes, and hospitals — received $3.5 billion in funding from the National Institutes of Health. Massachusetts-headquartered companies raised $3.26 billion in venture capital funding. Among all drugs in the development pipeline in the United States, 15 percent were being made by companies headquartered in Massachusetts. But actions taken by President Trump and his administration — cutting funding for scientific research and universities, flirting with tariffs, fanning skepticism about vaccines — threaten to devastate the ecosystem. Today, the industry is at a precipice, and uncertainty abounds. Some companies are already feeling the pinch of terminated federal grants, while others are anxious about what might come. Taken together, Trump's policies could force some companies and scientists to take their money, talents, and products overseas. Advertisement Christopher Locher, CEO of Lowell-based Versatope Therapeutics, which develops a platform to deliver vaccines and therapeutics, said he worries the Greater Boston life sciences ecosystem is 'being flushed down the toilet.' For example, Trump is Trump's funding cuts are already having a large impact on some local companies. Part of the problem is the Trump administration isn't only cutting funding, but it's picking which technologies to fund — in some cases apparently based on politics more than science. Take flu vaccines. The Trump administration recently announced a $500 million campaign to fund the development of a universal flu vaccine, which doesn't require annual updates, using technology being worked on But simultaneously, he cut funding for other work on a universal flu vaccine. Versatope Therapeutics got $14 million in NIH funding and spent five years developing a universal flu vaccine. It had approval from the US Food and Drug Administration to begin clinical trials when Trump terminated the contract's remaining $8 million, with the reason given being 'convenience,' Locher said. Trump also Advertisement Company executives say decisions by Trump officials to disinvest in vaccine-related technology — and concerns about whether government will approve new technology — means it's nearly impossible to find private investment funding to replace lost federal dollars. 'We're faced with bankruptcy in the very near future,' Locher said. Ironically, given Trump's stated commitment to bringing businesses back to the United States, one potential option Locher is eyeing is opening a subsidiary abroad. Conducting clinical trials would be cheaper in another country, whether in Europe, Australia, or China, Locher said, and some countries are offering financial incentives to American companies to relocate. Companies also face a potential workforce brain drain. There have been MassBio officials said China has less rigorous — but faster — safety and research protocols than the US. Australia allows a faster timeline for clinical trials. If regulatory approval of medicines is held up because the FDA is understaffed, companies may seek European regulatory approval instead. The loss of talent to foreign countries will be compounded if the pipeline of local university graduates dries up. One draw for life sciences companies to Boston/Cambridge is the presence of elite schools like Harvard and MIT, with their potential for faculty collaboration and skilled graduates. Advertisement Trump is trying to Chip Clark, CEO at Vibrant Biomedicines in Cambridge, said cuts to university research funding both 'shrink the pipeline of great ideas' that form the basis for many biotech startups and translate to fewer available scientists. Clark said the administration's policies 'seem like a deliberate attempt to try to cede scientific leadership to Europe and Japan and Korea and China. ... They will be delighted to capitalize on our talent, technology, and investment capital to make their robust biotech sectors grow and ultimately compete successfully against the US industry,' he said. Don Ingber, founding director of the Wyss Institute for Biologically Inspired Engineering at Harvard University, said he has postdocs with US visas applying for jobs in Europe, and others who were accepted to work at Harvard but are going elsewhere. 'The fact that places like Harvard and MIT and American universities are magnets for the best and brightest from around the world is what's driven our technology economy and certainly the Boston/Cambridge ecosystem,' Ingber said. 'With this uncertainty, I fear we'll lose a generation.' Ingber, who was forced to stop work on two government-funded projects on drugs designed to prevent injury from radiation exposure, compared administration policies to 'eating seed corn' needed to grow crops. Advertisement Trump's vendetta will undermine one of the most vibrant state economies in the country and set back American science by years. And it's not just eastern Massachusetts that will pay a price; the entire country will. As Ingber noted, it might take years to see the impact of medicines or technologies that aren't developed because of these shortsighted cuts. Editorials represent the views of the Boston Globe Editorial Board. Follow us
Epoch Times
15 hours ago
- Epoch Times
Nasal, Baby Teething Swabs Recalled Nationwide Over Microbial Contamination Fears
New Jersey-based Church & Dwight Co., Inc. is recalling three nasal and baby teething swab products due to potential fungal contamination in the cotton swab components, the company said in a June 6 The recall is applicable to three products: Zicam Cold Remedy Nasal Swabs designed to tackle the common cold, Zicam Nasal AllClear Swabs used for cleansing, and Orajel Baby Teething Swabs aimed at soothing teething discomfort among toddlers and infants.
Business Upturn
15 hours ago
- Business Upturn
HepatoBurn Announces Official Website Update Featuring Natural Daily Supplement for Metabolic Health and Liver Function
Taylor, June 07, 2025 (GLOBE NEWSWIRE) — HepatoBurn, a U.S.-based wellness brand, has updated its official website to share new information about its natural daily supplement formulated to support metabolic health and liver function in adults. Now available nationwide, the plant-based formula is positioned as a convenient, routine-friendly option for individuals seeking natural metabolic balance and detox support. According to the official product website ( HepatoBurn is designed to work synergistically with the body's internal systems to help maintain a healthy metabolism and support the liver's natural detoxification processes. The company emphasizes ease of use, noting that the supplement fits into everyday routines without the need for restrictive diets or complex wellness regimens. 'We created HepatoBurn to help individuals feel more energized, supported, and balanced,' said a company spokesperson. 'Our goal is to simplify wellness through science-backed, natural ingredients that integrate into daily life.' The company confirms that HepatoBurn is manufactured in U.S.-based facilities following rigorous safety and quality control standards. While the formula's specific ingredients are detailed on the official website, the product is crafted for adults seeking support with healthy energy levels, metabolic efficiency, and overall wellness. As stated on the site, first-time customers are backed by a satisfaction guarantee. Those interested in learning more about HepatoBurn, its intended benefits, and how to purchase directly can access full product details, FAQs, and secure ordering options through the official website. About HepatoBurn HepatoBurn is a Michigan-based wellness brand committed to delivering natural health supplements that are easy to use, transparent in formulation, and built for daily lifestyle integration. The company's mission is to help adults pursue optimal wellness through trustworthy, quality-driven solutions. Product and Contact Information Brand: HepatoBurn Website: Email: [email protected] Phone: +1 855-391-2736 Mailing Address: 22701 Trolley Industrial Dr Suite C, Taylor, MI 48180, USA Disclaimer This release is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. The statements made about this product have not been evaluated by the Food and Drug Administration. Individual results may vary. Consumers should consult a qualified healthcare provider before beginning any new dietary supplement. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
